New Positive Results for Fitusiran Presented at WFH

New Positive Results for Fitusiran Presented at WFH

New positive results from an interim analysis of the Phase 2 open-label extension (OLE) study of fitusiran, in development for the treatment of hemophilia A or B, with or without inhibitors, were presented at the World Federation of Hemophilia (WFH) Virtual Summit, held June 14-19, 2020.

Read the press release

View the presentation

In the data presented at WFH, monthly subcutaneous dosing with fitusiran in patients (N = 34) with moderate or severe hemophilia A and B, with and without inhibitors, demonstrated a durable therapeutic effect, including sustained lowering of antithrombin, increased thrombin generation, and low overall annualized bleed rate (median 0.84) in the median observation period of 36 months.

Long-term exposure to fitusiran in the Phase 2 OLE study reveals a safety profile that is supportive of continued evaluation of fitusiran in the ongoing Phase 3 ATLAS program.

Sanofi Genzyme is leading and funding the global development of fitusiran and will commercialize fitusiran, if successful.


Receive news and updates on the work at Alnylam that affects you most.